Linked here is a detailed quantitative analysis of Kimberly-Clark Co. (KMB). Below are some highlights from the above linked analysis:
Company Description: Kimberly Clark Corp. is a global consumer products company's producing tissue, personal care and health care products. Its brands include Huggies, Pull-Ups, Kotex, Depend, Kleenex and Scott tissue.
Monday, September 30, 2013
Sunday, September 29, 2013
Weekly Links: September 29, 2013
Each Sunday I highlight any notable articles that I came across over the past week, along with any Carnivals I participated in. For those readers not familiar with carnivals, it's where personal finance bloggers submit their best articles of the week with one blog serving as the host. The entries are separated into various categories such as Investing, Credit, Debt, Budgeting, Frugality, Wealth Building, Money Management, Financial Planning, Insurance, Taxes, The Economy, Real Estate, et. al.
Labels:
Links
Friday, September 27, 2013
5 Dividend Stocks Turbo-Charging Returns With Increased Dividends
It is a well-documented fact that a significant portion of the historical equity returns are a result of reinvested dividends. In Triumph of the Optimists: 101 Years of Global Investment Returns (2002), the authors looked at equity returns from capital gains and dividends from 1900 to 2000. They determined that performance in any given year was driven by capital appreciation, but long-term returns were largely the result of reinvested dividends.
Labels:
Increases
Thursday, September 26, 2013
Abbvie Inc. (ABBV) Dividend Stock Analysis
Linked here is a detailed quantitative analysis of Abbvie Inc. (ABBV). Below are some highlights from the above linked analysis:
Company Description: Abbvie Inc. is a global research-based pharmaceuticals business that emerged as a separate entity following its spin-off from Abbott Laboratories at the start of 2013. AbbVie's key drug is Humira for rheumatoid arthritis.
Company Description: Abbvie Inc. is a global research-based pharmaceuticals business that emerged as a separate entity following its spin-off from Abbott Laboratories at the start of 2013. AbbVie's key drug is Humira for rheumatoid arthritis.
Labels:
Analysis
Tuesday, September 24, 2013
Why We Are Dividend Growth Investors
We have all heard it... Stodgy, for old people, yawn, boring! These have all been used to describe dividend growth investing. As a dividend growth investor, I sometimes think our strategy is the most misunderstood. It seems everyone understands a traders mentality as evidenced by the numerous comments on capital appreciation - "Why would you buy that stock? It has been flat for 2 years."
Most understand the high yield investors mentality as noted by comments like - "Why would you buy that stock when you can buy Amalgamated Risk and it pays a 9% dividend?" Both of these strategies can be successful, as can a dividend growth strategy. Periodically, it is good to remind ourselves why we are dividend growth investors.
Most understand the high yield investors mentality as noted by comments like - "Why would you buy that stock when you can buy Amalgamated Risk and it pays a 9% dividend?" Both of these strategies can be successful, as can a dividend growth strategy. Periodically, it is good to remind ourselves why we are dividend growth investors.
Labels:
Classics,
Commentary
Monday, September 23, 2013
General Dynamics (GD) Dividend Stock Analysis
Linked here is a detailed quantitative analysis of General Dynamics (GD). Below are some highlights from the above linked analysis:
Company Description: General Dynamics is the world's fourth largest military contractor and also one of the world's biggest makers of corporate jets.
Company Description: General Dynamics is the world's fourth largest military contractor and also one of the world's biggest makers of corporate jets.
Labels:
Analysis
Subscribe to:
Posts (Atom)






